{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:09Z","timestamp":1792652109581,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14311-9","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:07:44Z","timestamp":1747674464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Venetoclax and hypomethylating agents versus induction chemotherapy for newly diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Yun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"6","key":"14311_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","volume":"37","author":"C Rausch","year":"2023","unstructured":"Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37(6):1234\u201344.","journal-title":"Leukemia"},{"key":"14311_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"7","key":"14311_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"14311_CR4","doi-asserted-by":"publisher","first-page":"11013","DOI":"10.1182\/blood-2022-168352","volume":"140","author":"D Keerty","year":"2022","unstructured":"Keerty D, Haddad PA. Comparative efficacy of targeted therapies in old unfit intermediate to high-risk patients with acute myeloid leukemia: a meta-analysis of comparative studies. Blood. 2022;140:11013.","journal-title":"Blood"},{"issue":"15","key":"14311_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1182\/blood.2023020102","volume":"142","author":"J Xie","year":"2023","unstructured":"Xie J, Bao X, Xue S-L, Shen H, Cen J, Yao L, et al. Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML. Blood. 2023;142(15):1323\u20137.","journal-title":"Blood"},{"issue":"24","key":"14311_CR6","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565\u201373.","journal-title":"Blood Adv"},{"issue":"3","key":"14311_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","volume":"96","author":"A Maiti","year":"2021","unstructured":"Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021;96(3):282\u201391.","journal-title":"Am J Hematol"},{"issue":"8","key":"14311_CR8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.26991","volume":"98","author":"AH Matthews","year":"2023","unstructured":"Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, et al. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. 2023;98(8):1254\u201364.","journal-title":"Am J Hematol"},{"issue":"13","key":"14311_CR9","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6(13):3997\u20134005.","journal-title":"Blood Adv"},{"issue":"12","key":"14311_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"11","key":"14311_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"23","key":"14311_CR12","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"22","key":"14311_CR13","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Ravandi F, O\u2019Brien S, Cortes J, Faderl S, Garcia-Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422\u20139.","journal-title":"Blood"},{"issue":"31","key":"14311_CR14","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H, N\u00f8rgaard M, Andersen MK, Dufva IH, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33(31):3641\u20139.","journal-title":"J Clin Oncol"},{"key":"14311_CR15","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed). 2021;372: n71.","journal-title":"BMJ (Clinical research ed)"},{"issue":"9","key":"14311_CR16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"14311_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","volume":"102","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, et al. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol. 2023;102(4):749\u201354.","journal-title":"Ann Hematol"},{"issue":"1","key":"14311_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-022-01229-z","volume":"15","author":"NJ Short","year":"2022","unstructured":"Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, et al. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022;15(1):12.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"14311_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41408-023-00948-x","volume":"13","author":"M Wang","year":"2023","unstructured":"Wang M, Cao HY, Tan KW, Qiu QC, Huang YH, Ge SS, et al. Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study. Blood Cancer J. 2023;13(1):173.","journal-title":"Blood Cancer J"},{"issue":"2","key":"14311_CR20","first-page":"237","volume":"19","author":"D Jin","year":"2024","unstructured":"Jin D, Chen H, He J, Li Y, Zheng G, Yang Y, et al. Impact of AML1\/ETO fusion on the efficacy of venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia. Target Oncol. 2024;19(2):237\u201349.","journal-title":"Target Oncol"},{"issue":"1","key":"14311_CR21","first-page":"96","volume":"32","author":"XX Liu","year":"2024","unstructured":"Liu XX, Wen XL, Li RQ, Zhang XL, Zhang TB, Dong CX, et al. Short-term effect of venetoclax combined with azacitidine and \u201c7+3\u201d regimen in the treatment of newly diagnosed elder patients with acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024;32(1):96\u2013103.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"8","key":"14311_CR22","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ajh.26941","volume":"98","author":"NG Daver","year":"2023","unstructured":"Daver NG, Iqbal S, Huang J, Renard C, Lin J, Pan Y, et al. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol. 2023;98(8):1176\u201384.","journal-title":"Am J Hematol"},{"key":"14311_CR23","doi-asserted-by":"crossref","unstructured":"Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, et al. Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia\u2014a multicenter cohort study. Am J Hematol. 2024.","DOI":"10.1002\/ajh.27366"},{"issue":"6","key":"14311_CR24","doi-asserted-by":"publisher","first-page":"E196","DOI":"10.1002\/ajh.26157","volume":"96","author":"A Salhotra","year":"2021","unstructured":"Salhotra A, Aribi A, Ngo D, Zhang J, Sandhu K, Al-Malki M, et al. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351). Am J Hematol. 2021;96(6):E196-e200.","journal-title":"Am J Hematol"},{"issue":"4","key":"14311_CR25","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","volume":"38","author":"S Shimony","year":"2024","unstructured":"Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, et al. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 2024;38(4):762\u20138.","journal-title":"Leukemia"},{"issue":"12","key":"14311_CR26","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.3390\/cancers15123210","volume":"15","author":"D Zhao","year":"2023","unstructured":"Zhao D, Zarif M, Zhou Q, Capo-Chichi J-M, Schuh A, Minden MD, et al. TP53 Mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell transplantation. Cancers. 2023;15(12):3210.","journal-title":"Cancers"},{"issue":"7","key":"14311_CR27","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","volume":"4","author":"CA Lachowiez","year":"2020","unstructured":"Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020;4(7):1311\u201320.","journal-title":"Blood Adv"},{"issue":"3","key":"14311_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100017","volume":"1","author":"J Othman","year":"2024","unstructured":"Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, et al. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia. 2024;1(3): 100017.","journal-title":"Blood Neoplasia"},{"key":"14311_CR29","doi-asserted-by":"crossref","unstructured":"Lu J, Xue S, Wang Y, Dai H-P, He X, Hu X, et al. Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial. Blood. 2023;142(Supplement 1):970-.","DOI":"10.1182\/blood-2023-181347"},{"issue":"9","key":"14311_CR30","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/ajh.26630","volume":"97","author":"A Tefferi","year":"2022","unstructured":"Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, et al. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022;97(9):1127\u201334.","journal-title":"Am J Hematol"},{"issue":"2","key":"14311_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99(2):193\u2013202.","journal-title":"Am J Hematol"},{"issue":"3","key":"14311_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/bloodadvances.2023011219","volume":"8","author":"M Ravindran","year":"2024","unstructured":"Ravindran M, Mozessohn L, Cheung M, Buckstein R, Teichman J. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML. Blood Adv. 2024;8(3):629\u201339.","journal-title":"Blood Adv"},{"issue":"1","key":"14311_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","volume":"34","author":"R Bisaillon","year":"2020","unstructured":"Bisaillon R, Moison C, Thiollier C, Krosl J, Bordeleau ME, Lehnertz B, et al. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia. 2020;34(1):63\u201374.","journal-title":"Leukemia"},{"issue":"11","key":"14311_CR34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791\u2013803.","journal-title":"Blood"},{"issue":"1","key":"14311_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","volume":"16","author":"NG Daver","year":"2023","unstructured":"Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H, et al. Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. J Hematol Oncol. 2023;16(1):19.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"14311_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41408-022-00670-0","volume":"12","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, et al. Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022;12(5):77.","journal-title":"Blood Cancer J"},{"issue":"12","key":"14311_CR37","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.26724","volume":"97","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, et al. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022;97(12):1560\u20137.","journal-title":"Am J Hematol"},{"issue":"10","key":"14311_CR38","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia. Haematologica. 2022;107(10):2501\u20135.","journal-title":"Haematologica"},{"issue":"12","key":"14311_CR39","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/ajh.26731","volume":"97","author":"D Rivera","year":"2022","unstructured":"Rivera D, Kim K, Kanagal-Shamanna R, Borthakur G, Montalban-Bravo G, Daver N, et al. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022;97(12):1599\u2013606.","journal-title":"Am J Hematol"},{"issue":"13","key":"14311_CR40","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, et al. Impact of Venetoclax and Azacitidine in Treatment-Na\u00efve Patients with Acute Myeloid Leukemia and IDH1\/2 Mutations. Clin Cancer Res. 2022;28(13):2753\u201361.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"14311_CR41","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood.2020010165","volume":"137","author":"M Duchmann","year":"2021","unstructured":"Duchmann M, Micol JB, Duployez N, Raffoux E, Thomas X, Marolleau JP, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021;137(20):2827\u201337.","journal-title":"Blood"},{"key":"14311_CR42","unstructured":"Nct. Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML. 2021.\u00a0"},{"key":"14311_CR43","unstructured":"Nct. Venetoclax + Azacitidine vs. Induction Chemotherapy in AML. 2021."},{"key":"14311_CR44","unstructured":"Nct. Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment. 2022."},{"key":"14311_CR45","unstructured":"Nct. Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial). 2022."},{"key":"14311_CR46","unstructured":"Nct. Testing the effects of novel therapeutics for newly diagnosed, untreated patients with high-risk acute myeloid leukemia (A MyeloMATCH Treatment Trial). 2022."},{"key":"14311_CR47","unstructured":"Nct. VA vs DA for newly diagnosed hig-risk AML. 2023."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14311-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14311-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14311-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:07:49Z","timestamp":1747674469000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14311-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14311"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14311-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"14 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"894"}}